key: cord-0283330-x2tox53i
authors: McCulloch, Laura; Harris, Alison J.; Malbon, Alexandra; Daniels, Michael J. D.; Younas, Mehwish; Grainger, John R.; Allan, Stuart M.; Smith, Craig J.; McColl, Barry W.
title: Treatment with IgM-enriched intravenous immunoglobulins (IgM-IVIg) enhances clearance of stroke-associated bacterial lung infection
date: 2021-12-16
journal: bioRxiv
DOI: 10.1101/2021.12.16.472965
sha: e4317436a22bc2b5f904b4e34357250bb2d8d669
doc_id: 283330
cord_uid: x2tox53i

Post-stroke infection is a common complication of stroke that is associated with increased mortality and morbidity. We previously found that experimental stroke induces an ablation of multiple sub-populations of B cells and reduced levels of IgM antibody that coincide with the development of spontaneous bacterial pneumonia. Reduced circulating IgM concentrations were also observed in acute stroke patients. The loss of IgM antibody after stroke could be an important determinant of infection susceptibility and highlights this pathway as an important target for intervention. We treated mice with a low (replacement), dose of IgM-enriched intravenous immunoglobulin (IgM-IVIg) prior to and 24 h after experimental stroke induced by middle cerebral artery occlusion (MCAO) or sham surgery, then recovered mice for 2 d or 5 d. The effect of treatment on lung bacterial burden, lung pathology, brain infarct volume, antibody levels and both lung and systemic cellular and cytokine immune profiles was determined. Treatment with IgM-IVIg enhanced bacterial clearance from the lung after MCAO and improved pathology but did not impact infarct volume. IgM-IVIg treatment induced immunomodulatory effects systemically including rescue of splenic plasma B cell numbers and endogenous mouse IgM and IgA circulating immunoglobulin concentrations that were reduced by MCAO, and treatment also reduced concentrations of pro-inflammatory cytokines in the lung. The effects of MCAO and IgM-IVIg treatment on the immune system were tissue specific as no impact on B cells or mouse immunoglobulins were found within the lung. However, the presence of human immunoglobulins from the IgM-IVIg treatment led to increased total lung immunoglobulin concentration. IgM-IVIg treatment did not increase the number of lung mononuclear phagocytes or directly modulate macrophage phagocytic capacity but enhanced their capability to phagocytose Staphylococcus aureus bioparticles in vitro by increasing opsonisation. Low dose IgM-IVIg contributes to increased clearance of spontaneous lung bacteria after MCAO likely via increasing availability of antibody in the lung to enhance phagocytic activity. Immunomodulatory effects of IgM-IVIg treatment, including reduced pro-inflammatory cytokine production, may also contribute to reduced levels of damage in the lung after MCAO. IgM-IVIg shows promise as an antibacterial and immunomodulatory agent to use in the treatment of post-stroke infection. GRAPHICAL ABSTRACT

Improvements in hyper acute stroke care and recent advances made using thrombectomy for removal of large vessel clots have led to an extensive reduction in mortality from ischaemic stroke 1 . However recovery of patients is often compromised by physical disability, mental health issues and cognitive impairment 2-4 . Infection is also a serious complication of stroke affecting up to 30 % of patients and infections in both the acute and chronic phase of stroke recovery are associated with increased mortality and disability, and cognitive decline [5] [6] [7] [8] . Indeed, the impact of infection on stroke recovery is so extensive that preventing complications of stroke, such as pneumonia, was listed in the top 10 priorities for stroke research in a recent report from the Stroke Priority Setting Partnership (SPSP) 9 .

Ischaemic stroke induces rapid immune suppression which is thought to contribute to infection risk in patients 10, 11 . Our previous studies identified an early loss of B cells, including marginal zone (MZ) B cells, after experimental stroke with an associated reduction in circulating concentration of IgM antibodies, and the development of spontaneous bacterial pneumonia 12 . Reduced IgM concentrations were similarly measured in blood samples from patients within one week of ischaemic stroke, compared to controls of similar age and sex distribution 12, 13 . MZ B cell production of IgM provides crucial early defence against systemic infection, in particular infections caused by encapsulated bacteria 14, 15 , which are implicated in pneumonia complicating stroke 16 . Therefore, reductions in B cells and their production of antibody may be an important determinant of infection susceptibility after stroke.

Intravenous immunoglobulin (IVIg) is a therapeutic agent prepared from pooled serum from thousands of healthy blood donors. Low (replacement) doses of IVIg intended to restore natural circulating antibody concentrations, can be used to treat both primary and secondary immunodeficiencies 17, 18 . At higher doses, IVIg has potent anti-inflammatory properties and has been beneficial in the treatment of autoimmune diseases including Kawasaki disease, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP) 19, 20 . IgM is the most potent antibacterial antibody isotype as its multi-valent structure results in high antigen avidity and LPS-neutralising abilities and potent agglutination and complement fixing properties [21] [22] [23] . IVIg has been used in experimental animal models to treat bacterial pneumonias 24, 25 . Furthermore, IgM-enriched preparations of intravenous immunoglobulin (IgM-IVIg) showed improved efficacy in reducing bacteraemia in animal models of pneumonia and sepsis 26, 27 and have progressed to clinical trials with improved outcome reported in specific patient sub-groups [28] [29] [30] . Given the antibacterial properties of IgM, and the depleted circulating IgM concentration in patients after acute ischaemic stroke, IgM-IVIg may be a useful therapeutic agent for pneumonia complicating stroke.

Here we show that treatment with IgM-IVIg enhanced the clearance of bacteria and reduced infection- Mice were maintained under specific pathogen free (SPF) conditions and a standard 12 h light/dark cycle with unrestricted access to food and water. Mice were housed in individually ventilated cages in groups of up to 6 and were acclimatized for a minimum of 1 week before procedures. All animal experiments were carried out under the authority of a UK Home Office Project Licence in accordance with the 'Animals (Scientific procedures) Act 1986' and Directive 2010/63/EU and were approved by the University of Edinburgh's Animal Welfare and Ethics Review Board. Experimental design, analysis and reporting followed the ARRIVE 2.0 guidelines 31 . The IMPROVE guidelines were followed to refine procedures and improve animal welfare after MCAO 32 .

Middle cerebral artery occlusion (MCAO) surgery was performed under isoflurane anaesthesia induced at 3% and maintained at 1.4% with O2 and N2O by insertion of a 6-0 nylon monofilament with a 2-mm silicone coated tip (210 μm diameter; Doccol) through the external carotid artery and advanced through the internal carotid artery to occlude the MCA. The filament was withdrawn after 30 min to allow reperfusion, the neck wound sutured and the animals recovered. Topical local anaesthetic (Lidocaine 4%) was applied to the wound. For sham surgery, the filament was advanced to the MCA and immediately retracted. Sham-operated animals remained anaesthetized for 30 min and recovered as above. Core body temperature was maintained at 37±0.5 °C throughout the procedure with a feedback controlled heating blanket (Harvard Apparatus). Animals were recovered for 2 or 5 d then euthanised using a rising concentration of CO2 followed by exsanguination.

IgM-IVIg (Pentaglobin; Biotest) was aliquoted neat and given to animals at 250 mg/ kg body weight. HSA (Biotest) was given to animals at 50 mg/ kg. Dilution of control was advised by manufacturer to replicate the use of HSA in clinical trials, where a 5 x lower concentration is used to mimic the foaming, colour and viscosity of IgM-IVIg and therefore assists with protecting blinding when used as a placebo.

Treatments were numbered and randomly assigned to animals allowing the surgeon to be blinded to the treatment throughout procedures and welfare assessment during recovery. Treatment was administered intravenously, prior to MCAO or sham surgery and 24 h post-surgery.

Tissue harvests were carried out in a laminar flow cabinet under aseptic conditions. Following euthanasia, the peritoneal cavity was carefully opened and a 23G needle with a 1cm length of sterile polyethylene tubing (Thermo Fisher) over tip was inserted through the diaphragm. Dulbecco's Phosphate Buffered Saline (800 l; dPBS; Thermo Fisher) was flushed into the pleural cavity then retrieved using a 1 ml syringe and repeated twice more to obtain a pleural cavity lavage sample. A cardiac blood sample, anti-coagulated with 3.8% w/v tri-sodium citrate, was taken. Half of the sample was stored on ice for bacteriological analysis, the remaining half was spun at 400 x G for 10 min, plasma removed and stored at -80 °C for analysis of soluble mediators. A clean 23G needle with polyethylene tubing was inserted into the trachea and tied in place. dPBS (800 l) was flushed into the lungs and retrieved using a 1 ml syringe to obtain a bronchial-alveolar lavage (BAL) sample. BAL samples were centrifuged at 800 x G for 10 min and supernatant stored as BAL fluid (BALF). Lungs, heart and thymus were removed from the thoracic cavity as one, with the needle still tied in the trachea. The inferior lobe of the right lung was tied off and removed into a gentleMACS™ C tube (Miltenyi Biotech) containing 1 ml of sterile dPBS for analysis of bacterial load. The middle and superior lobes of the right lung were tied off and removed into a cryovial and snap frozen on dry ice. 800 l of 4% buffered paraformaldehyde (PFA) was used to inflate the left lung lobe via a needle in the trachea and intact heart, thymus, lung were dropped into a bijou tube of 4 % PFA. After 24 h of immersion fixation, the left lung lobe was dissected from tissue, processed and routinely embedded in paraffin blocks for histology. Next the spleen was dissected, weighed and halved. Half was snap frozen in a cryovial over dry ice for immunostaining whilst the other half was taken into a bijou tube and stored on ice for flow cytometry.

Finally, the brain was removed and frozen in cold isopentane over dry ice and stored in a bijou tube at -80 °C.

Flow cytometry of the lungs at 2 d post sham or MCAO surgery was carried out in a separate cohort of animals. Animals were euthanised in a rising concentration of CO2 followed by exsanguination. Pleural cavity lavage was taken as previously described. BAL was also taken as above, however the lungs were flushed three times with 800 l dPBS to maximise cellular harvest. The entire lung was dissected into 1 ml cold RPMI 1640 medium (RPMI; Thermo Fisher). Samples were stored on ice until processed for flow cytometry.

Post-hoc exclusions of tissues for analysis were applied as follows. Animals that did not have infarcts affecting the cortex and striatum after MCAO surgery were completely excluded from the study as an unsuccessful MCAO (n=5). For lung pathology, lungs that were not fully inflated before fixation and 

Coronal cryosections (20 m) were taken at 400 m intervals from fresh frozen brains and stained with Harris Haematoxylin stain-acidified (CellPath) and Eosin Y (CellPath) (H&E). Briefly, sections were hydrated by soaking for 2 min each in 100% > 95% > 80% > 70% ethanol, then distilled water. Slides were stained with haematoxylin for 5 min, washed in distilled water, immersed in Scott's tap water (CellPath) for 30 s followed by a 30 s wash in distilled water. Sections were then stained with eosin for 3 min and washed with distilled water. Sections were dehydrated by soaking for 2 min in 70% > 80% > 95% > 100% ethanol, fixed for 5 min in xylene, then coverslips were applied using DPX mountant (Merck). Sections were scanned on an Axio Scan.Z1 (Zeiss) and visualized using Zeiss Zen 3.2 blue edition software. Sections identified by neuroanatomical landmarks at 8 specific coronal levels for quantification as described in 33 . The infarcted area for each region (cortex, striatum/pallidum, hippocampus, thalamus and other) at each of the 8 coronal levels was quantified using Fiji (U. S. National Institutes of Health, USA https://imagej.nih.gov/ij/) and summed to give a total for each section. These values were plotted against distance from rostral pole and area under the curve calculations performed in Prism (GraphPad Prism v9) to calculate infarct volume.

The inferior lobe of the right lung was homogenised in 1 ml sterile dPBS using a gentleMACS (Miltenyi Biotech). In a laminar flow hood, lung homogenates and blood, collected as described above, were serially diluted from neat to 10 -6 in sterile dPBS and dilutions plated onto Columbia agar with horse blood for a general bacteria screen or MaConkey's agar to assess gut-derived bacteria. Plates were incubated at 37 °C for 48 h and bacterial colonies counted.

Sections (4 m) were cut from inflated left lungs embedded in paraffin wax blocks. Sections were dewaxed in xylene and then stained with H&E as above. Pathology was assessed by a board-certified veterinary pathologist, who was blinded to treatment groups, using scoring criteria described in results for this analyte were not reported. Plasma samples were added to plate at a 1/10 dilution and BALF samples were added to plate as previous. In all assays, samples were assayed as single replicates and all samples, standards and quality controls were prepared in accordance with the manufacturer's instructions. Samples were incubated with beads on a plate for 1 h (isotyping assay) at room temperature or overnight (cytokine assay) at 4° C and washes carried out using a magnetic plate washer. Plates were analysed using a Magpix™ Luminex® machine and Luminex xPonent® software version 4.2, with a sample volume of 50 l per well and a minimum of 50 events counted per sample.

Spleens were disrupted with a syringe plunger and passed through a 100 M cell sieve. Red blood cells were lysed with red blood cell lysing buffer Hybri-MaxTM (Sigma) before counting live cells with trypan blue (Sigma) exclusion. Splenocytes were plated at 2 million cells/well and incubated with Zombie UV (Biolegend) for dead cell discrimination, then Fc blocked with normal mouse serum Cells were fixed using a formaldehyde-based fixation buffer (Biolegend) and analysed within 48 h on a 5-laser LSR Fortesssa (Becton Dickinson). Data analysis was performed on Flowjo (Treestar), with FSCA/FSCH doublet exclusion and dead cell exclusion. Spleens were weighed then divided into two in order to perform both flow cytometry and IHC. The weight of each half as a proportion of the total weight was used to convert the cell count for flow cytometry into an estimated total for the whole spleen as follows:

Absolute cell count = [population as % of live leukocytes x trypan blue total cell count x (total spleen weight/ weight of spleen used for cell isolation)].

Acetone fixed 6 µm spleen sections were blocked with normal goat serum (Sigma). For detection of germinal centres, sections were labelled with rat anti-mouse B220 (Biolegend RA3-6B2) followed by goat anti-rat AF594 secondary antibody (Thermo Fisher). Sections were washed and subsequently incubated with AF647-conjugated lectin peanut agglutinin (PNA; Thermo Fisher) in the presence of sodium azide and bovine serum albumin overnight at 4°C.

Bone marrow single cell suspensions were made by flushing cells from the femurs and tibias of C57Bl/6J mice into sterile dPBS. Cells were resuspended in RPMI containing 10% foetal bovine serum (Thermo Fisher) and 1% Penicillin-Streptomycin (Thermo Fisher) and 25% conditioned media from L929 cells and incubated at 37°C with 5% CO2. Cultures were supplemented with fresh medium at 24 h. After 7 d, differentiated bone marrow-derived macrophages (BMDM) were transferred to a 96 well plate at 5 x10 5 cells/ ml and incubated for 24 h prior to use in assay. Cells were either untreated or given treatment 0.25 mg/ml or 2 mg/ ml IgM-IVIg, control 0.05 mg/ml or 0.4 mg/ml HSA and returned to incubator for 4 h. After incubation with treatment, cells were either "washed" in PBS with fresh RPMI replaced or left "unwashed" and proceeded directly to next step of assay. Plate was inserted into an IncuCyte® S3 Live-Cell Analysis System (Sartorius) for a single phase-contrast read in order to determine cell count. 10 M Cytochalasin D was added to negative control wells for 10 min, then pHrodo® Red Staph. aureus BioParticles® (Thermo Fisher) were diluted 1:4 in RPMI and 10 l added to each well of cells. Plates were then returned to the IncuCyte® and imaged every 5 min for 2.5 h on both phase-contrast and 'Red' channels (400 ms exposure time). Cell-by-cell analysis was performed on Incucyte® analysis software, using a mask to automatically identify (1) all BMDM, using phase contrast and (2) "red objects" i.e. BMDM that have phagocytosed pHrodo® Red bioparticles.

Thresholds for size and fluorescence were adjusted during a pilot experiment, to eliminate non-specific signal while maximising detection of phagocytosing cells, with visual inspection of multiple FOVs to check sensitivity and accuracy. Integrated density of red fluorescent signal was measured at each time point and was normalised to the total number of macrophages present in the well at the beginning of assay.

Sample sizes were estimated from previous data on reduced IgM concentration and reduced splenic MZ B cells after experimental stroke 12 using power analysis carried out on InVivoStat software (http://invivostat.co.uk/) to be sensitive to a 35% effect of experimental stroke at 80% statistical power at a 5 % significance level. Animals were ear notched for identification and randomised to experimental groups (sham or MCAO surgery and treatment) using a computer-based random number generator (https://www.randomizer.org/) and treatments were administered in a blinded manner and allocation of treatment was concealed throughout study. Animals were given an experimental identifier and all samples were analysed using this coded identifier. Data was unblinded for analysis after experimental work was complete.

For normally distributed data, differences were tested using unpaired Student's t-test or 2-way analysis variance (ANOVA) with Tukey multiple comparison test. Results were displayed as mean ± standard deviation. When data were non-normally distributed, log transformation was used to normalise data sets and data were then analysed as previous. Non-parametric tests, such as Mann-Whitney test, were used to analyse data produced from scoring systems and results were displayed as violin plots. Data were analysed using GraphPad Prism. In all experiments, values of P≤0.05 were accepted as statistically significant. demonstrating that reduced bacterial counts were a direct effect of the treatment and not due to alterations in primary stroke pathology.

Lung pathology was assessed using a scoring system that accounted for perivascular edema, inflammation in the perivascular and peribronchiolar regions, macrophages in the alveolar spaces and macrophages/ hypercellularity in the interstitium (Supplementary Figure 2) . At 2 d post-surgery, a low level of lung pathology was seen in sham-operated animals, regardless of treatment, which may be due to the time under inhalational anaesthesia during surgery. At 2 d post-MCAO, lung pathology scores were significantly increased in HSA treated animals, whereas in IgM-IVIg treated animals there was no difference to sham-operated controls ( Figure 1E, F) . A trend for reduced lung pathology scores in IgM-IVIg treated animals was also observed at 5 d after MCAO (Figure 1E, G) .

Associations between lung pathology and bacterial burden, or stroke severity, were explored using these data. There was a modest association between lung pathology and bacterial burden at 2 d and 5 d post MCAO ( Figure 1H , I) and between lung pathology and infarct volume at 2 d post MCAO in HSA treated animals. The association between lung pathology and bacterial burden was not observed in IgM-IVIg treated animals but there was an association between lung pathology and infarct volume at 2 d post MCAO. Consistent with previous data showing that IgM-IVIg did not alter brain infarct volume, this indicates that IgM-IVIg treatment modulates the association between bacterial burden and lung pathology observed in HSA treated controls. Furthermore, as bacterial burden and lung pathology were altered to different degrees in IgM-IVIg treated animals, some lung pathology may be driven by the stroke itself, in addition to that caused by infection. Figure 1J) . There was no difference in mortality between treatment groups at 2 d post-stroke, however reduced mortality was seen in IgM-IVIg treated mice at 5 d (Supplementary Figure 1K) .

These data demonstrate that low dose IgM-IVIg enhances the clearance of spontaneous bacterial infection after experimental stroke. IgM-IVIg treatment led to reduced lung pathology in comparison to HSA treated animals with equivalent bacterial burden or stroke severity. Furthermore, although an early increase in weight loss is seen in IgM-IVIg treated animals, there were no adverse effects of IgM-IVIg treatment on primary stroke pathology, welfare or mortality.

We next wanted to determine that IgM-IVIg treatment was present both systemically, and within the lung, after intravenous administration. As IgM-IVIg is pooled from human donors, multiplex ELISA to detect human immunoglobulins can be used to distinguish the presence of IgM-IVIg from endogenously produced mouse immunoglobulin. Human immunoglobulin subsets IgM, IgG1, IgG2, IgG3, IgG4 and IgA were significantly increased in the plasma of animals receiving IgM-IVIg treatment at 2 d post MCAO or sham surgery (Figure 2A-F) . Low levels of some immunoglobulin isotypes were detected in HSA treated animals, indicating a mild cross reactivity of assay with endogenous mouse immunoglobulin, however the presence of human immunoglobulins were clearly detected above this background in IgM-IVIg treated animals (Figure 2A-F) . Human immunoglobulins were also detected in BALF, although at relatively lower concentrations than detected in plasma ( Figure 2G-L) . The proportion of IgM, IgA and total IgG detected in plasma and BALF was compared to the original IgM-IVIg treatment. There was proportionally less IgM in the BALF than was detected in the plasma or in the original IgM-IVIg treatment ( Figure 2M ). These data demonstrate that IgM-IVIg-derived human immunoglobulins can be detected both systemically, and within the lung, after intravenous administration. However there may be relatively less access of human IgM to the lung compartment than other immunoglobulin isotypes. 

Experimental stroke is known to result in lymphopenia, and in particular a loss of B cells and circulating antibodies, which is thought to contribute to the onset of spontaneous bacterial pneumonias 12 .

Furthermore, IgM signalling via the Fcreceptor can have autocrine effects on B cell development and activation 35 . We therefore characterised the effects of experimental stroke on B cell subpopulations and endogenous mouse immunoglobulins and determined if these were altered by treatment with IgM-IVIg. Supplementary Fig 3A, B) . In confirmation, MCAO-induced reduction in total spleen leukocytes was also unaltered by treatment with IgM-IVIg ( Figure 3B) . Furthermore, total CD19 + splenic B cells were reduced by MCAO, but unaffected by treatment with IgM-IVIg ( Figure 3C) . Figure 4B ). In contrast to splenic B cell numbers ( Figure 3C) , total CD20 + B cells were not reduced by MCAO but were reduced by IgM-IVIg treatment in both sham and experimental stroke animals ( Figure 4C ).

to bacterial infection ( Figure 4D) . A trend for lower levels of plasma cells was seen in the lungs of IgM-IVIg treated mice after MCAO, but not sham, surgery ( Figure 4D) . As there was no effect in sham 

Antibodies are capable of directly lysing bacteria however they can also aid clearance by coating the surface of bacteria enhancing uptake by phagocytes in a process known as opsonophagocytosis 37 .

Therefore, we next examined the effects of MCAO and IgM-IVIg treatment on lung mononuclear phagocytes. Flow cytometry was used to detect myeloid cells in the lung ( Figure 5A) . The lung contains two major populations of macrophages, the alveolar macrophage and the interstitial macrophage, although heterogeneity exists within these broad categorisations 38 . Alveolar macrophages, which are the majority population, were not affected by MCAO or by treatment with IgM-IVIg ( Figure   5B ). In contrast, interstitial macrophages were reduced after MCAO and further reduced after treatment with IgM-IVIg ( Figure 5C ). Interstitial macrophages can be repopulated from blood-derived monocytes 38 . There was no difference in total monocyte numbers, or Ly6C lo and Ly6C hi functionally distinct monocyte subsets in the lung after MCAO or IgM-IVIg treatment ( Figures 5D, E, F 

suggesting that a lack of precursors was not responsible for the reduction in interstitial macrophages. Figure 4A) and reduced the number of eosinophils in the lung (Supplementary Figure 4B) . Lung T cells, dendritic cells and NK cells were unaffected by either MCAO or IgM-IVIg treatment (Supplementary Figures 4C, F) .

We next used multiplex ELISA to profile the cytokine environment in the lung after MCAO and treatment with IgM-IVIg. MCAO induced an increase in GM-CSF ( Figure 5G ) and TNF  ( Figure   5H ) concentrations in the BALF, likely a response to post-stroke bacterial pneumonia. Treatment with IgM-IVIg reduced the concentrations of these inflammatory cytokines. Stroke also increased the concentration of IL-33 in the BALF, however this was unaffected by IgM-IVIg treatment (Supplementary Figure 5A ). There were no significant differences in concentrations of IL-6, IFN , IL-1, Il-2, IL-4, IL-10 and IL-12. However IL-6 and IFN  showed the same trend of a MCAO-induced increase which was blunted after treatment with IgM-IVIg (Supplementary Figures 5B-H) .

We next wanted to understand if IgM-IVIg might influence macrophage function, notably, anti-bacterial phagocytic activity given that lung macrophages will be exposed to elevated exogenous immunoglobulin levels after IgM-IVIg treatment (Figure 2) . Macrophages express multiple Fc receptors which can have both activating and inhibitory effects 39 In contrast, when IgM-IVIg was washed from cells prior to the addition of pHrodo bioparticles, no effect of IgM-IVIg at low or high dose were observed ( Figure 5H ). The density of internalised pHrodo bioparticles per cell was calculated at 90 min after the addition of pHrodo across three independent experiments. This confirmed low dose IgM-IVIg significantly increased phagocytosis of pHrodo bioparticles when present throughout the assay, however this effect was lost when IgM-IVIg was washed prior to incubation with bioparticles ( Figure 5I , J).

In conclusion, these data show that reduced bacterial load in the lungs of IgM-IVIg treated mice is not associated with an increased abundance of mononuclear phagocytes within the lung. Certain proinflammatory cytokines elevated after MCAO were dampened after treatment with IgM-IVIg.

Furthermore, IgM-IVIg does not directly alter the capabilities of macrophages to phagocytose bacteria in vitro, but instead at low dose (but not high dose), enhances phagocytosis via bacterial opsonisation. 

We describe here the effects of low dose of IVIg (i.e. antibody replacement dose), enriched for IgM in the context of stroke-associated infection. Our key in vivo findings are that IgM-IVIg enhances the clearance of bacterial infection and reduces lung pathology and inflammatory cytokines levels alongside systemic B cell composition and antibody levels following experimental stroke. We also observed that IgM-IVIg enhanced bacterial opsonophagocytosis by macrophages in vitro, a potential mechanism contributing to enhanced bacterial clearance in vivo. Infections are a frequent complication of stroke, affecting up to 30% of stroke patients, and independently affect functional outcome and survival when experienced during the acute and chronic phase of stroke recovery [5] [6] [7] [8] . Bacterial pneumonias have the greatest impact on clinical outcome and are associated also with further complications such as recurrent stroke 41, 42 . Currently there are no available treatments to prevent pneumonia as prophylactic antibiotic treatment after stroke had no effect on pneumonia incidence or clinical outcome in randomised trials 43, 44 . In recent years we have learned that ischemic stroke induces early changes to systemic immune function including atrophy of secondary lymphoid organs, reduced numbers of lymphocytes 10, 12, [45] [46] [47] [48] and functional deficiencies in B cell 12 , T cell 45 , NKT cell 49 and monocyte [50] [51] [52] populations. Preventing some of the immunosuppressive effects of stroke, or selectively restoring immune function may provide alternative or adjunct therapies to reduce infection incidence and improve outcome and long-term survival after stroke. However, infiltration of certain immune cell populations into the brain and associated inflammatory responses are known to exacerbate brain injury 53 . Therefore any attempts to enhance immune function to prevent infection must be targeted to prevent unfavourable effects on the developing stroke lesion and processes influencing repair and recovery.

There are 5 main classes of immunoglobulins; IgG, IgM, IgA, IgD and IgE, which all have different properties and functions 54 . In this study we have used an IgM-enriched preparation of IVIg, Pentaglobin™, which contains 72% IgG, 12%IgM and 16% IgA. This is similar to the proportion of antibodies naturally occurring in serum 54 , unlike conventional IVIG which is comprised of >96% IgG antibodies. IgM is known to be the most potent antibacterial immunoglobulin due to its highly effective agglutination and complement fixation properties 55 . Immunosuppressed patients with selective IgM deficiency often present with recurring respiratory infections 56 . Those with agammaglobulinemia, where production of all immunoglobulin isotypes is impaired, who were given IgG only immunoglobulin replacement therapy had recurrent bacterial lung infections that resulted in chronic lung disease in some 57 . In vitro assays showed Pentaglobin™ had a greater opsonic activity against Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli, in comparison to standard IVIg 22, 27 which are some of the common bacterial species that cause pneumonia in stroke patients 58 . Our data, confirm and expand on these findings, demonstrating that at low dose this effect is solely due to opsonisation of bacteria and does not directly influence macrophage phagocytic capacity. However at high dose, the presence of IgM-IVIg actually inhibits this process. In addition to its use in infection prevention, conventional IVIg has also been used at high doses in experimental stroke, where it had immunomodulatory and anti-inflammatory properties and reduced infarct size via supressing TLR responses to damage-associated molecular patterns (DAMPs) and suppressing inflammasome-mediated and complement-mediated neuronal cell death [59] [60] [61] [62] [63] [64] . Therefore it is unlikely that an IVIg immunomodulatory approach after stroke will worsen injury in the brain. In this study, stroke infarct size was unaffected by treatment with low dose IgM-IVIg (Supplementary Figure 1) , which supported that effects on bacterial load are a direct consequence of its anti-bacterial properties and not due to altering stroke severity. However there may be a dose which confers both anti-infective and brain reparative properties and further studies are warranted to investigate this potential.

Potential harmful effects of IgM-IVIg treatment in the context of cerebrovascular disease also require consideration. IVIg is known to increase serum viscosity and one of the reported adverse effects in a minority population is thromboembolic events, including stroke 65 . Often IVIg is given as a continuous infusion to minimise effects on blood viscosity. In this study, IgM-IVIg was given as a single bolus pre-surgery and again at 24 h. Treatment had no adverse effects on animal welfare except for a small increase in body weight loss which normalised by 5 d (Supplementary Figure 1) . Mortality rates were similar between groups at 2 d and improved in IgM-IVIg treated animals at 5 d post experimental stroke (Supplementary Figure 1) . Our data, together with previous studies, further substantiate the favourable preclinical safety profile of IVIg treatment in stroke.

Low dose IVIg is used as an anti-infective agent in immunosuppressed patients rather than for its immunomodulatory properties reported at high doses. However even at these low doses we saw immunomodulatory effects on plasma B cells and antibodies in the spleen (Figure 3 ). This is in agreement with reports that show IVIg can induce proliferation and immunoglobulin production in B cells from immunosuppressed patients 66 in plasma B cells observed in the lung after MCAO was not associated with an increase in endogenous mouse immunoglobulins demonstrating that although B cell populations persist in the lung, they may be functionally impaired. Despite this, total lung antibodies were increased by the provision of IgM-IVIg ( Figure 2) and we demonstrated ex vivo that these have the capacity to improve phagocytosis via opsonisation of bacteria. In addition, the mice treated with IgM-IVIg showed lower pathology scores. This may be in part due to the reduced bacterial loads present in these animals ( Figure 1A-D) , however bacterial load was not significantly associated with pathology score in IgM-IVIg treated animals in contrast to the association observed in controls (Figure 1 H, I) . This may be in part due to the reduced presence of pro-inflammatory cytokines such as GM-CSF and TNF which are known to be associated with exacerbated pathology in other respiratory lung diseases, such as SARS-CoV2, and have therefore been proposed as targets for clinical intervention 69, 70 In conclusion, we propose that treatment with IgM-IVIg offers potential as a safe and effective method to reduce bacterial load and pathology in the lung after stroke. Further preclinical studies are warranted to optimise dosing regimen, including in combination with antibiotics, and at delayed time points after MCAO to better understand the translational potential of IgM-IVIg as an anti-infective agent for stroke patients. Modulation of dose may be able to harness direct systemic anti-bacterial and neuroimmunomodulatory properties to result in a treatment with dual benefits by preventing infection and reducing harmful aspects of brain inflammation in stroke patients.

Executive summary Part 2: Burden of Stroke in the next 20 years and potential returns from increased spending on research

Cognitive rehabilitation and recovery after stroke

Is stroke the most common cause of disability?

Post-stroke infection: A systematic review and meta-analysis

Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial

Infections Up to 76 Days After Stroke Increase Disability and Death

Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke

Association S. The Stroke Priority Setting Partnership results for investment

Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke

Cellular Immunodepression Preceding Infectious Complications after Acute Ischemic Stroke in Humans

Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke

Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence

Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens

Marginal zone B-cells, a gatekeeper of innate immunity

Microbiological Etiologies of Pneumonia Complicating Stroke. A Systematic Review

Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review

The antiinflammatory IgG

Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective

Anti-Inflammatory Actions of Intravenous Immunoglobulin

The importance of natural IgM: scavenger, protector and regulator

Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin

Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant

Effect of intravenous immunoglobulin on the function of Treg cells derived from immunosuppressed mice with Pseudomonas aeruginosa pneumonia

IVIG-mediated protection against necrotizing pneumonia caused by MRSA

Immunoglobulin M-enriched intravenous polyclonal immunoglobulins reduce bacteremia following Klebsiella pneumoniae infection in an acute respiratory distress syndrome rat model

In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens

Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis

Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)

The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research

The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments)

Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia

The effect of pneumonia on mortality among patients hospitalized for acute stroke

sIgM-FcμR Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection

B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection

Beyond binding: antibody effector functions in infectious diseases

The interstitial macrophage: A longneglected piece in the puzzle of lung immunity

The function of Fcγ receptors in dendritic cells and macrophages

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages

Diagnosis of Stroke-Associated Pneumonia: Recommendations From the Pneumonia in Stroke Consensus Group

Interrelationship among common medical complications after acute stroke: pneumonia plays an important role

Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial

The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial

Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation

Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke

Splenic Atrophy in Experimental Stroke Is Accompanied by Increased Regulatory T Cells and Circulating Macrophages

Importance of T Lymphocytes in Brain Injury, Immunodeficiency, and Recovery after Cerebral Ischemia

Functional Innervation of Hepatic iNKT Cells Is Immunosuppressive Following Stroke

Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia -The PREDICT study

Monocytes Are Major Players in the Prognosis and Risk of Infection After Acute Stroke

Blocking Stroke-Induced Immunodeficiency Increases CNS Antigen-Specific Autoreactivity But Does Not Worsen Functional Outcome after Experimental Stroke

Inflammation and Stroke: An Overview

Structure and function of immunoglobulins

IgM and its receptors: Structural and functional aspects

Selective IgM Deficiency: Clinical and Laboratory Features of 17 Patients and a Review of the Literature

Low IgA and IgM Is Associated with a Higher Prevalence of Bronchiectasis in Primary Antibody Deficiency

Aspiration pneumonia after stroke: intervention and prevention

Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death

Intravenous Immunoglobulin Reduces Infarct Volume but Not Edema Formation in Acute Stroke

Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke

The effects of intravenous immunoglobulin on cerebral ischemia in rats: An experimental study

Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia

Combination Therapy with Low-Dose IVIG and a C1-esterase Inhibitor Ameliorates Brain Damage and Functional Deficits in Experimental Ischemic Stroke

Strokes, thromboembolic events, and IVIg: Rare incidents blemish an excellent safety record

Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies

Elimination of complement fixation of gamma-globulin by chemical modification with beta-propiolactone

Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies

We thank staff in the University of Edinburgh biological research facility on the Edinburgh Bioquarter campus for animal husbandry and technical support, in particular Will Mungall who performed all of the i.v. tail vein injections of treatment. We thank staff in the QMRI Flow Cytometry and cell sorting facility (University of Edinburgh) for their support in generating the flow cytometry data and staff at 

No competing interests to declare.

 Figure 2 Criteria for scoring lung pathology Scoring system used to grade the extent of pathology in lung from animals treated with HSA or IgM-IVIG 2 days and 5 days after sham or MCAO surgery (Figure 1 ). Goblet cell hyperplasia was not detected in any animals. All animals had <25% alveolar spaces with macrophages present and scored 1. Inflammation did not reach a score of 3 in any animals. Scores in sham-operated animals mainly consisted of edema and some with mild inflammation. Scale bars 50 mm.Supplementary Figure 3 Splenic B cell responses to IgM-IVIg Spleen weight, normalised to total body weight, is significantly reduced by stroke (A) but there is no effect of treatment with IgM-IVIg at